UK Study to Evaluate the Safety & Effectiveness of KM001, a potential treatment for PC

Kamari Pharma is happy to announce the initiation of a new study in UK to evaluate the safety and efficacy of KM001-a new potential treatment for PC and PPPK1 patients.

KM001 is a novel, small molecule which acts as TRPV3 inhibitor- a protein that plays essential role in keratoderma and itch development and formulated into a topical cream.

The KM001 cream is already tested in a phase 1b study in Israel, enrolling PC and PPPK1 patients and recently a new study was initiated at Prof Edel O’Toole site in Royal London Hospital. The study is a proof-of-concept study and will enrol up to 10 patients, for a treatment period of 12 weeks.

Kamari Pharma hopes that the results of these studies will be able to support further development of the KM001 topical cream, which may provide a new solution for patients with PC and PPPK1.

PC News and Events

Click here for PC Project News and Events webpage which includes announcements of upcoming events, important news information as well as links to all PC Patient NewsBrief issues and IPCC Newsletter issues.
PC Patient Registry
Learn why this international registry of PC patients is so crucial to the worldwide efforts to find treatments and a cure for PC